{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:29:18Z","timestamp":1781065758631,"version":"3.54.1"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Invasive aspergillosis and mucormycosis are life-threatening infections in solid organ and hematopoietic cell transplant recipients. Despite medical advancements in the care of these patients and the availability of new mold-active drugs, the outcomes remain suboptimal. Therefore, there has been increased interest in the use of combination antifungal therapy, in hopes that leveraging the possible in vitro synergy of these agents will improve the prognosis of invasive mold disease. However, there has been a large disconnect between the results of experimental and clinical investigations, as clinical studies have not unequivocally demonstrated the superiority of combination therapy over monotherapy. This is particularly true for mucormycosis, where the rarity of the condition has made it nearly impossible to prospectively study novel therapeutic strategies. We review the current standard of antifungal therapy and the preclinical and clinical data addressing the merit of combination therapy, and we provide guidance to optimize the management of these mycoses.<\/jats:p>","DOI":"10.1097\/tp.0000000000002353","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T22:56:24Z","timestamp":1530658584000},"page":"1815-1823","source":"Crossref","is-referenced-by-count":17,"title":["How We Approach Combination Antifungal Therapy for Invasive Aspergillosis and Mucormycosis in Transplant Recipients"],"prefix":"10.1097","volume":"102","author":[{"given":"Ghady","family":"Haidar","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Singh","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section, University of Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 4","key":"bib1-20231002","first-page":"228","article-title":"Aspergillosis in solid organ transplantation","volume":"13","year":"2013","journal-title":"Am J Transplant"},{"key":"bib2-20231002","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","year":"2009","journal-title":"Clin Infect Dis"},{"key":"bib3-20231002","doi-asserted-by":"crossref","first-page":"ofx050","DOI":"10.1093\/ofid\/ofx050","article-title":"Infections in hematopoietic cell transplant recipients: results from the organ transplant infection project, a multicenter, prospective, cohort study","volume":"4","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"bib4-20231002","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","year":"2002","journal-title":"Blood"},{"key":"bib6-20231002","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","year":"2010","journal-title":"Clin Infect Dis"},{"key":"bib7-20231002","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1086\/605445","article-title":"Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome","volume":"200","year":"2009","journal-title":"J Infect Dis"},{"key":"bib8-20231002","first-page":"1629","article-title":"Mucormycosis in organ and stem cell transplant recipients","volume":"54","year":"2012","journal-title":"Clin Infect Dis"},{"key":"bib9-20231002","doi-asserted-by":"crossref","first-page":"ofw268","DOI":"10.1093\/ofid\/ofw268","article-title":"Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000-2013","volume":"4","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"bib10-20231002","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"bib11-20231002","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3324\/haematol.2012.065110","article-title":"Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)","volume":"98","year":"2013","journal-title":"Haematologica"},{"key":"bib12-20231002","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.49.2.721-727.2005","article-title":"Caspofungin inhibits Rhizopus oryzae 1,3-beta-d-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis","volume":"49","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"bib15-20231002","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1093\/jac\/dkx295","article-title":"Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation","volume":"72","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"bib16-20231002","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"bib17-20231002","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In vitro activity of isavuconazole and comparators against clinical isolates of the mucorales order","volume":"59","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"bib19-20231002","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/infdis\/151.5.902","article-title":"The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis","volume":"151","year":"1985","journal-title":"J Infect Dis"},{"key":"bib20-20231002","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000238524","article-title":"Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice","volume":"33","year":"1987","journal-title":"Chemotherapy"},{"key":"bib21-20231002","first-page":"296","article-title":"In vivo synergy of amphotericin b plus posaconazole in murine Aspergillosis","volume":"60","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"bib22-20231002","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1128\/AAC.00597-13","article-title":"Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: effect of serum on inhibitory and fungicidal interactions","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"bib23-20231002","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1128\/AAC.03261-14","article-title":"In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds","volume":"58","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"bib24-20231002","first-page":"457","article-title":"Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis","volume":"55","year":"2017","journal-title":"Med Mycol"},{"key":"bib25-20231002","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1128\/AAC.00329-09","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis","volume":"53","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"bib26-20231002","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkw276","article-title":"Dose optimization of voriconazole\/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic\/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis","volume":"71","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"bib27-20231002","article-title":"Combination therapy with isavuconazole and micafungin for treatment of experimental invasive pulmonary Aspergillosis","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"bib28-20231002","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","year":"2015","journal-title":"Ann Intern Med"},{"key":"bib29-20231002","article-title":"Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive Aspergillosis","volume":"62","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"bib32-20231002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejmech.2017.07.030","article-title":"Repurposing antipsychotic drugs into antifungal agents: synergistic combinations of azoles and bromperidol derivatives in the treatment of various fungal infections","volume":"139","year":"2017","journal-title":"Eur J Med Chem"},{"key":"bib33-20231002","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s13104-017-2696-4","article-title":"The in vitro effects of interferon-gamma, alone or in combination with amphotericin B, tested against the pathogenic fungi Candida albicans and Aspergillus fumigatus","volume":"10","year":"2017","journal-title":"BMC Res Notes"},{"key":"bib34-20231002","article-title":"Rifampin enhances the activity of amphotericin B against Fusarium solani species complex and Aspergillus flavus species complex isolates from keratitis patients","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"bib35-20231002","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","year":"2007","journal-title":"Clin Infect Dis"},{"key":"bib36-20231002","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1002\/cncr.25312","article-title":"Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"bib37-20231002","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.leu.2405065","article-title":"Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin","volume":"22","year":"2008","journal-title":"Leukemia"},{"key":"bib38-20231002","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","article-title":"Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study","volume":"81","year":"2006","journal-title":"Transplantation"},{"key":"bib39-20231002","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","year":"2004","journal-title":"Clin Infect Dis"},{"key":"bib40-20231002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2334-7-28","article-title":"Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients","volume":"7","year":"2007","journal-title":"BMC Infect Dis"},{"key":"bib41-20231002","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","volume":"53","year":"2006","journal-title":"J Infect"},{"key":"bib42-20231002","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.23109","article-title":"Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial)","volume":"110","year":"2007","journal-title":"Cancer"},{"key":"bib43-20231002","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1002\/cncr.22348","article-title":"Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis","volume":"107","year":"2006","journal-title":"Cancer"},{"key":"bib44-20231002","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2014.08.012","article-title":"Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies","volume":"45","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"bib45-20231002","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/cncr.21057","article-title":"Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis","volume":"103","year":"2005","journal-title":"Cancer"},{"key":"bib46-20231002","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/jof1020252","article-title":"Diagnostic modalities for invasive mould infections among hematopoietic stem cell transplant and solid organ recipients: performance characteristics and practical roles in the clinic","volume":"1","year":"2015","journal-title":"J Fungi (Basel)"},{"key":"bib47-20231002","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijid.2014.07.007","article-title":"Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis","volume":"28","year":"2014","journal-title":"Int J Infect Dis"},{"key":"bib48-20231002","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood-2011-03-316430","article-title":"How I treat mucormycosis","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib49-20231002","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","article-title":"Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice","volume":"49","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"bib50-20231002","first-page":"1556","article-title":"Combination echinocandin-polyene treatment of murine mucormycosis","volume":"5","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"bib51-20231002","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","year":"2008","journal-title":"Clin Infect Dis"},{"key":"bib52-20231002","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1128\/AAC.00628-08","article-title":"Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae","volume":"52","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"bib53-20231002","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/AAC.01124-08","article-title":"Posaconazole mono- or combination therapy for treatment of murine zygomycosis","volume":"53","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"bib54-20231002","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkw433","article-title":"Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis","volume":"72","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"bib55-20231002","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/AAC.01577-10","article-title":"Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins","volume":"55","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"bib56-20231002","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.48.5.1664-1669.2004","article-title":"In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus","volume":"48","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"bib57-20231002","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1093\/jac\/dkr297","article-title":"In vitro interaction of caspofungin and immunosuppressives against agents of mucormycosis","volume":"66","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"bib58-20231002","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(10)70316-9","article-title":"Mucormycosis: its contemporary face and management strategies","volume":"11","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"bib59-20231002","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1128\/AAC.50.1.96-103.2006","article-title":"Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole","volume":"50","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"bib60-20231002","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/nm1108-1155","article-title":"Graft-versus-host disease: suppression by statins","volume":"14","year":"2008","journal-title":"Nat Med"},{"key":"bib61-20231002","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1172\/JCI32338","article-title":"The iron chelator deferasirox protects mice from mucormycosis through iron starvation","volume":"117","year":"2007","journal-title":"J Clin Invest"},{"key":"bib62-20231002","doi-asserted-by":"crossref","first-page":"811.e1","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"bib63-20231002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MPH.0b013e3181ca0dcf","article-title":"Successful triple combination therapy of disseminated absidia corymbifera infection in an adolescent with osteosarcoma","volume":"32","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"bib64-20231002","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial","volume":"67","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"bib65-20231002","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/13693780802326001","article-title":"Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?","volume":"47","year":"2009","journal-title":"Med Mycol"},{"key":"bib66-20231002","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline: a reality check","volume":"16","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"bib67-20231002","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"bib68-20231002","first-page":"S73","article-title":"Combination therapy for mucormycosis: why, what, and how?","volume":"54","year":"2012","journal-title":"Clin Infect Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007890-201811000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:01:09Z","timestamp":1696222869000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201811000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002353","relation":{},"ISSN":["1534-6080","0041-1337"],"issn-type":[{"value":"1534-6080","type":"electronic"},{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}